References
- Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-8
- Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8
- Brown DM, Campochiaro PA, Singh RP, et al.; for the CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-33
- Campochiaro PA, Heier JS, Feiner L, et al.; for the BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12
- Brown DM, Kaiser PK, Michels, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;334:1432-44
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for age-related macular degeneration. N Engl J Med 2006;355:1419-31
- Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials. Ophthalmology 2013;120:2013-22
- Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48
- Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014;121:2247-54
- Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-203
- Vorum H, Olesen T, Jinck J, Hedegaard M. Real world evidence of use of anti-VEGF use in Denmark. Curr Med Res Opin 2016. doi: 10.1080/03007995.2016.1221803
- Chakravarthy U, Harding SP, Rogers CA, et al.; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomized controlled trial. Lancet 2013;382:1258-67
- Peden MC, Suñer IJ, Hammer ME, Grizzard WS. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology 2015;122:803-8
- Stewart MW. Individualized therapy of neovascular age-related macular degeneration: what are patients gaining? Or losing? J Clin Med 2015;4:1079-101
- Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015;122:146-52
- Available at: http://retinatoday.com/2014/08/long-acting-anti-vegf-delivery [Last accessed 15 January 2016]
- Kiss S. Key learnings from a phase 2 study of encapsulated cell therapy for the treatment of neovascular AMD. Presented at the American Society of Retinal Specialists Annual Meeting. San Francisco, CA, USA, 11 August 2016
- Heier J. AVA-101 Gene Therapy for Neovascular AMD: Fifty-Two-Week Trial Results From the Phase 2a Clinical TrialAVA-101 Gene Therapy for Neovascular AMD: Fifty-Two-Week Trial Results From the Phase 2a Clinical Trial. Presented at the 2015 American Academy of Ophthalmology Annual Meeting. Las Vegas, NV, USA, 15 November 2015
- Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012;153:209-13